This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

ACE inhibitors in chronic kidney disease (CKD)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • renin-angiotensin system blockade reduces proteinuria and retards chronic kidney disease progression independent of blood pressure lowering
    • nephroprotection reflects both hemodynamic and nonhemodynamic mechanisms that culminate in attenuation of proinflammatory and profibrotic mediators in the renal parenchyma
    • angiotensin-converting enzyme (ACE) inhibitors were originally shown to retard progression of type 1 diabetic nephropathy (1)
    • ACE inhibitors are more effective than other antihypertensives in slowing progression of nondiabetic kidney disease (2)
  • a review found that the effectiveness of ACE inhibitors is similar across various baseline risks for disease progression in non-diabetic nephropathy (3)
    • however when stratified according to degree of proteinuria
      • among the subgroup of patients with proteinuria > or =500 mg/d, significant treatment effect was seen across all patients with a measurable outcome risk, including those at relatively low risk (1.7% annualized risk for progression).
      • there was no benefit of ACEI therapy among patients with proteinuria <500 mg/d, even among higher risk patients (control outcome rate 19.7%)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.